acut
bronchiti
ill
frequent
encount
primarycar
physician
inflamm
tracheobronchi
tree
result
respiratori
tract
infect
character
persist
cough
sputum
product
occasion
accompani
fever
andor
chest
pain
acut
bronchiti
may
viral
bacteri
origin
often
treat
antibiot
four
clinic
trial
conduct
compar
high
low
dose
loracarbef
new
antibiot
three
agent
commonli
use
treat
acut
bronchiti
amoxicillinclavulan
cefaclor
amoxicillin
result
studi
indic
loracarbef
mg
twice
daili
clinic
bacteriolog
efficaci
common
respiratori
pathogen
streptococcu
pneumonia
haemophilu
influenza
moraxella
branhameua
catarrhali
compar
compar
agent
loracarbef
well
toler
cefaclor
amoxicillin
moreov
produc
significantli
lower
incid
diarrhea
amoxicillinclavulan
loracarbef
may
consid
safe
effect
altern
agent
treatment
patient
acut
bronchiti
cute
bronchiti
ill
frequent
encount
primarycar
physician
inflamm
tracheobronchi
tree
result
respiratori
tract
infect
virus
well
bacteri
respiratori
pathogen
implic
etiolog
acut
bronchiti
unfortun
howev
identif
specif
caus
agent
hamper
difficulti
obtain
reliabl
sputum
sampl
cultur
result
consider
controversi
regard
best
cours
treatment
condit
patient
acut
bronchiti
suspect
viral
origin
often
treat
acetaminophen
cough
suppress
symptomat
relief
bacteri
origin
either
suspect
document
antibiot
routin
use
treatment
newer
antibiot
current
test
determin
efficaci
ill
acut
bronchiti
articl
review
etiolog
treatment
acut
bronchiti
well
safeti
efficaci
result
four
clinic
trial
design
compar
new
fllactam
antibiot
loracarbef
agent
current
use
therapi
patient
condit
patient
acut
bronchiti
gener
persist
cough
usual
accompani
sputum
product
occasion
fever
chest
pain
symptom
develop
quickli
usual
preced
upper
respiratori
tract
infect
factor
age
gener
health
patient
climat
exposur
air
pollut
cigarett
smoke
contribut
onset
sever
ill
etiolog
agent
like
caus
bronchiti
vari
age
patient
viral
pathogen
includ
respiratori
syncyti
viru
parainfluenza
viru
rhinoviru
influenza
viru
well
adenoviru
coronaviru
rubeola
viru
extent
bacteri
infect
implic
develop
acut
bronchiti
controversi
part
difficult
obtain
sputum
sampl
contamin
bacteria
normal
present
nasopharyng
tract
healthi
person
nevertheless
gener
agre
bacteri
invas
may
caus
prolong
ill
recogn
mycoplasma
pneumonia
bordetella
pertussi
potenti
primari
etiolog
agent
acut
bacteri
bronchiti
common
respiratori
bacteria
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
may
respons
secondari
bacteri
infect
addit
bacteri
pathogen
moraxella
branhamella
catarrhali
chlamydia
psittaci
may
also
play
role
develop
acut
bronchiti
date
five
random
placebocontrol
trial
conduct
assess
efficaci
antibiot
therapi
acut
bronchiti
result
trial
mix
addit
signific
unclear
rigor
diagnost
criteria
sputum
purul
pathogen
isol
pathogen
suscept
test
appli
four
five
studi
small
sampl
size
nevertheless
two
studi
demonstr
benefit
patient
receiv
treatment
symptom
improv
sputum
product
decreas
one
day
lost
work
also
decreas
result
anoth
studi
suggest
patient
chronic
obstruct
pulmonari
diseas
associ
risk
factor
dyspnea
increas
sputum
product
sputum
purul
constitut
subgroup
patient
acut
bronchiti
deriv
greatest
benefit
antibiot
therapi
estim
patient
acut
bronchiti
treat
antibiot
histor
commonli
use
antibiot
includ
erythromycin
tetracyclin
amoxicillin
well
ampicillin
trimethoprim
sulfamethoxazol
cefaclor
addit
drug
current
develop
enhanc
efficaci
improv
safeti
treatment
patient
loracarbef
member
carbacephem
class
filactam
antibiot
new
oral
agent
administ
twice
daili
carbacephem
chemic
similar
cephalosporin
except
sulfur
atom
replac
methylen
group
chang
dihydrothiazin
ring
cephalosporin
nucleu
tetrahydropyridin
ring
carbacephem
nucleu
substitut
confer
greater
stabil
carbacephem
loracarbef
activ
wide
rang
gramposit
gramneg
bacteri
pathogen
includ
thought
play
role
acut
bronchiti
four
clinic
trial
two
unit
state
two
europ
initi
studi
rel
effect
loracarbef
treat
acut
bronchiti
trial
design
twoarm
random
parallel
studi
compar
efficaci
loracarbef
anoth
antibiot
frequent
use
treat
acut
bronchiti
first
studi
compar
highdos
loracarbef
mg
twice
daili
amoxicillin
mg
three
time
daili
dere
wh
unpublish
data
second
trial
compar
lowdos
loracarbef
mg
twice
daili
amoxicillin
mg
three
time
daili
dere
wh
unpublish
data
remain
two
trial
one
compar
lowdos
loracarbef
standard
dose
cefaclor
mg
three
time
daili
compar
highdos
loracarbef
standard
dose
amoxicillinclavulan
mg
three
time
daili
regimen
administ
day
enrol
four
studi
patient
requir
diagnosi
acut
purul
bacteri
bronchiti
patient
cough
product
purul
sputum
confirm
microscop
examin
white
blood
cell
epitheli
cell
per
highpow
field
furthermor
ensur
infect
acut
patient
requir
experienc
rapid
onset
symptom
within
day
enrol
studi
patient
diagnos
chronic
bronchiti
infiltr
chest
radiograph
renal
impair
hypersensit
filactam
exclud
trial
pregnant
nurs
women
also
elig
patient
enrol
four
studi
total
receiv
highdos
loracarbef
receiv
lowdos
loracarbef
receiv
amoxiciuinclavulan
receiv
cefaclor
receiv
amoxicillin
dere
wh
unpublish
data
mani
patient
enrol
clinic
trial
qualifi
clinic
bacteriolog
evalu
disqualif
case
occur
pretherapi
evalu
sputum
cultur
yield
known
respiratori
pathogen
patient
consid
evalu
pure
mix
cultur
posit
one
follow
four
organ
h
influenza
pneumonia
catarrhali
haemophilu
parainfluenza
tabl
resist
respiratori
pathogen
antibiot
use
uncommon
treatment
group
four
studi
tabl
ii
dere
wh
unpublish
data
low
rate
resist
loracarbef
amoxicillinclavulan
cefaclor
unexpect
surprisingli
howev
level
resist
amoxicillin
particularli
h
influenza
although
higher
agent
also
rel
low
explan
may
like
studi
involv
amoxicillin
treatment
group
took
place
europ
preval
ofh
influenza
resist
amoxicillin
gener
lower
unit
state
determin
clinic
bacteriolog
respons
antibiot
therapi
patient
evalu
within
day
posttherapi
day
lateposttherapi
drug
discontinu
result
studi
shown
tabl
ii
dere
wh
unpublish
data
data
clear
clinic
bacteri
respons
highdos
lowdos
loracarbef
virtual
ident
addit
loracarbef
compar
clinic
bacteriolog
efficaci
compar
agent
rel
safeti
loracarbef
comparison
antibiot
also
address
studi
studi
compar
loracarbef
amoxicillinclavulan
similar
proport
patient
group
report
experienc
nausea
vomit
well
rash
cutan
manifest
hypersensit
tabl
iv
proport
patient
discontinu
therapi
also
compar
howev
significantli
greater
number
patient
amoxi
cephalothin
disk
use
test
suscept
cefaclor
mpicillin
use
test
suscept
amoxicillin
data
dere
wh
unpublish
data
cillinclavulan
group
report
experienc
diarrhea
studi
loracarbef
compar
cefaclor
safeti
profil
two
drug
similar
event
categori
tabl
v
also
true
advers
reaction
report
patient
receiv
treatment
highdos
loracarbef
lowdos
loracarbef
amoxicillin
tabl
vi
dere
wh
unpublish
data
summari
recent
clinic
trial
design
evalu
use
loracarbef
treat
acut
bronchiti
shown
loracarbef
clinic
well
bacteriolog
efficaci
similar
compar
drug
major
respiratori
pathogen
h
influenza
catarrhali
posttherapi
evalu
occur
day
therapi
discontinu
late
posttherapi
day
therapi
discontinu
clinic
success
refer
elimin
improv
symptom
bbacteriolog
success
refer
document
elimin
presum
elimin
patient
clinic
success
repeat
cultur
possibl
indic
sputum
product
resolv
pathogen
ioracarbef
mg
twice
daili
lowdos
ioracarbef
mg
twice
daili
data
dere
wh
unpublish
data
nausea
andor
vomit
rash
relat
term
patient
discontinu
due
advers
event
one
patient
report
experienc
nausea
vomit
diarrhea
record
categori
diarrhea
nausea
andor
vomit
adapt
permiss
common
advers
event
emerg
therapi
amoxicillin
vs
highdos
lowdos
loracarbef
